Interleukin 13 (IL13) belongs to a family of cytokines whose members exhibit structural homology, despite amino acid sequence dissimilarity. For example, while of limited sequence homology, IL13 and IL4 share a signaling receptor, IL13/4 receptor, on a variety of human normal cells. However, a subclass of IL4-independent IL13 receptors is overexpressed on certain transformed cells, including human malignant gliomas. We introduced mutations into human (h) IL13 to determine the site(s) involved in interaction with the shared receptor and/or the glioma-associated receptor. This analysis identified at least three protein regions that are needed for signaling through the shared receptor. These regions were localized to ␣-helices A, C, and D and were mainly separate from the region(s) needed to interact with the glioma-associated receptor. Glutamic acids at positions 13 and 16 in hIL13 ␣-helix A, arginine and serine at positions 66 and 69 in helix C, and arginine at position 109 in helix D were found to be important in inducing biological signaling since their specific mutation resulted in loss and/or gain of function phenomena. We demonstrate that the molecular requirements of hIL13 to interact with its respective receptors are generally distinct and can be controlled by mutagenesis of the cytokine.
Interleukin 13 (IL13) belongs to a family of cytokines whose members exhibit structural homology, despite amino acid sequence dissimilarity. For example, while of limited sequence homology, IL13 and IL4 share a signaling receptor, IL13/4 receptor, on a variety of human normal cells. However, a subclass of IL4-independent IL13 receptors is overexpressed on certain transformed cells, including human malignant gliomas. We introduced mutations into human (h) IL13 to determine the site(s) involved in interaction with the shared receptor and/or the glioma-associated receptor. This analysis identified at least three protein regions that are needed for signaling through the shared receptor. These regions were localized to ␣-helices A, C, and D and were mainly separate from the region(s) needed to interact with the glioma-associated receptor. Glutamic acids at positions 13 and 16 in hIL13 ␣-helix A, arginine and serine at positions 66 and 69 in helix C, and arginine at position 109 in helix D were found to be important in inducing biological signaling since their specific mutation resulted in loss and/or gain of function phenomena. We demonstrate that the molecular requirements of hIL13 to interact with its respective receptors are generally distinct and can be controlled by mutagenesis of the cytokine.
Human interleukin 13 (hIL13)
1 is a 114-amino acid cytokine secreted by activated T cells (1, 2) . hIL13 is involved in immunoregulatory functions by interacting with B cells, monocytes (2, 3) , and macrophages (4) . It can also act on somatic cells, such as endothelial cells (5) (6) (7) . Based on its predicted secondary structure, hIL13 has been added to a growing family of growth hormone-like cytokines that all exhibit bundled ␣-helical core topology (8) . Accordingly, hIL13 is a globular protein comprised mainly of four ␣-helical regions (helices A, B, C, and D) arranged in a "bundled core" (9) . Other members of the family include interleukin 4 (IL4), granulocyte macrophagecolony-stimulating factor, IL2, macrophage-colony-stimulating factor, and IL5 (10) .
Although hIL13 and hIL4 are dissimilar at the primary amino acid level, they share similar functions by binding to and signaling through a shared receptor complex (11, 12) . The shared IL13/4 receptor complex is a heterodimer comprised of an approximate 140-kDa subunit, p140 (13) , and an approximate 52-kDa subunit, ␣Ј also termed IL13R␣1 (14 -16) . hIL13 does not bind the p140 subunit of the shared receptor complex in the absence of ␣Ј, contrary to the ability of hIL4 to interact with it (17) . Although hIL13 and hIL4 use this shared receptor on some normal cells (18) and on some adenocarcinomas (19) , several other malignant cells, such as human malignant gliomas, express an abundance of a hIL13 receptor that is not shared with hIL4 (20, 21) . In addition, a protein has been currently identified that binds hIL13 avidly, with no affinity toward hIL4 (22) , but its role as a glioma-associated receptor for hIL13 remains to be demonstrated. Of importance, no cell signaling function has been assigned to this receptor (22, 23) .
Since IL13 and IL4 are believed to be structural homologs, primary amino acid sequence alignments between hIL4 and hIL13 were contributive in elucidating components of the shared IL13/4 receptor (1, 11) . By using the alignment data, we have begun rational mutational studies of hIL13 to identify regions of hIL13 needed for its interaction with the components of the shared receptor. We have previously reported a mutant form of hIL13, hIL13.E13K, which not only has an impaired signaling through the shared receptor but also has enhanced avidity toward the IL13 cancer-associated receptor (24) . Position 13 of hIL13 is, according to the sequence alignment data, equivalent to position 9 in hIL4. Suspecting this position in helix A to be a potential functional "hot spot," a more in-depth mutational study of this site was done by substituting the position 13 glutamic acid of hIL13 with several other amino acids. Table I shows each mutant made and the mutagenic DNA primer used in its synthesis. Additional sites in helix A were also investigated, the 16th-and 17th-position glutamic acids. These sites were of interest since a complete helical turn up from the 13th-position would bring positions 16 and 17 to the same face of the helix. Since in wild-type hIL13, all three positions are glutamic acid, it was plausible that the entire cluster of negative charge might participate in binding to the shared receptor. The third area of hIL13 mutated for study was in the C-helix, such as positions 66 and 69; the sequence alignment suggested this area may be analogous to position 88 in hIL4 (11) . The fourth area mutated was in ␣-helix D. Arginine at position 109 was changed to aspartic acid, an IL13 mutant homolog to hIL4.R121D (11, 25) ; phenylalanine at position 113 was changed to aspartic acid, representing an alignment equivalent to the IL4 counterpart, hIL4.Y124D antagonistic mutant (11, 25) .
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separate regions of hIL13, on non-contiguous ␣-helices A, C, and D, involved in signaling of hIL13 through the IL13/4 shared receptor. Furthermore, the identified region(s) of hIL13 that are important for signaling through the shared receptor are generally separate from or may eventually overlap with the site(s) that interacts with the cancer-associated receptor.
EXPERIMENTAL PROCEDURES

Materials
Unique site elimination mutagenesis kit, fast protein liquid chromatographic system, columns, and media were obtained from Amersham Pharmacia Biotech. Oligonucleotide primers were synthesized in house at the Macromolecular Core Laboratory, Pennsylvania State University College of Medicine. Polymerase chain reaction kit was from Perkin-Elmer. Tissue culture ware was from Corning Glass. 3-(4,5-Dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (inner salt)/phenazine methosulfate (MTS/ PMS) non-radioactive cell proliferation assay was purchased from Promega (Madison, WI). SDS-PAGE supplies were from Bio-Rad. Antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). SuperSignal Substrate for chemiluminescent detection was purchased from Pierce. Cell lines were obtained from the American Type Culture Collection (Manassas, VA).
Methods
Recombinant Protein Expression in a Prokaryotic System-All plasmids carrying the genes encoding proteins of interest were under a T7 promoter-based expression system. The plasmids were constructed as described (24) . BL21(DE3) Escherichia coli, which carries the T7 RNA polymerase gene in an isopropyl-1-thio-␤-galactopyranoside-inducible form, was used as the host for recombinant protein expression. Production of recombinant proteins driven by T7 RNA polymerase allowed production of milligram quantities of recombinant protein from a 1.0-liter culture induced at A 600 of 2.0.
For expression of proteins, competent BL21 cells were transformed with the appropriate plasmids and grown to A 600 equal to 2.0, at which point isopropyl-1-thio-␤-galactopyranoside was added to a final concentration of 250 M. Cells were harvested 90 min later. The inclusion body fraction of the cells was isolated and denatured in 7 M guanidine HCl and then renatured by rapid dilution into buffer, using the disulfideshuffling method as we have previously described (26) . After dialysis, the renatured proteins were purified using a Amersham Pharmacia Biotech fast protein liquid chromatography system.
Mutagenesis-Mutations of the hIL13 gene were made by standard polymerase chain reaction protocols (using the mutated oligonucleotides as sense or antisense primers in polymerase chain reaction) or by using a unique site elimination mutagenesis kit, based on the procedure developed by Deng and Nickoloff (27) . Primers used for the mutagenesis are shown in Table I . All mutated plasmids were isolated and sequenced, in house, to verify the correct mutation prior to use.
Polyacrylamide Gel Electrophoresis and Immunoblotting-Purity of the isolated recombinant proteins was determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, under nonreducing conditions. The separated proteins in the gel were stained either with Coomassie Blue for visual inspection or transferred to polyvinylidene difluoride membrane for Western blot analysis. For Western blot analysis, the polyvinylidene difluoride with the transferred proteins was incubated in 5% nonfat milk in phosphate-buffered saline (PBS) for 1 h at room temperature. The membrane was incubated for 1 h in 5% milk/PBS containing goat anti-human IL13 antibody (1:1,000 dilution). The antibody was raised against a hIL13-specific peptide located at the carboxyl terminus of hIL13. After incubation with the primary antibody, the membrane was washed three times, 5 min each, with 0.05% Tween 20/PBS. The membrane was then incubated for 1 h in 5% milk/PBS containing donkey anti-goat IgG conjugated with horseradish peroxidase (1:20,000 dilution). The membrane was washed three times, 5 min each, with 0.05% Tween 20/PBS. The immunoreactive proteins were identified on film, using enhanced chemiluminescence detection. Images were digitized using a Hewlett-Packard Scan-Jet 6100C scanner and composited using Microsoft Powerpoint software.
Circular Dichroism (CD)-CD spectra for the proteins were obtained over the wavelength range of 185-260 nm using a Jasco J-710 spectropolarimeter. All measurements were carried at 37°C, using the same cuvette, the same orientation of the cuvette to the light source, and a 2-mm light path. Proteins (0.1 mg/ml) were resuspended in phosphate-buffered saline (PBS) and then analyzed. For unfolded samples, protein was resuspended in 8 M urea containing 40 mM dithiothreitol (denaturation buffer). Reported spectra were the average of three consecutive runs for each sample. Spectra from appropriate blanks, PBS alone or denaturation buffer, were subtracted from each sample so that the resulting spectra reflected only the CD contribution of the proteins.
Cell Proliferation Assay-TF-1 cells (pre-leukemic human B cells, which express the shared IL13/4 receptor) (18, 11) were grown in the presence of different concentrations of wild-type interleukins or their mutants in 96-well culture plates. After 72 h of incubation at 37°C, the rate of proliferation of the TF-1 cells was determined by a colorimetric 
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well using a microplate reader. The wells with cells treated with high concentrations of cycloheximide served as background for the assay. Indirect Immunofluorescence-Human umbilical vein endothelial cells (HUVEC) were seeded onto an eight-chambered slide, 50,000 cells per chamber, and incubated overnight at 37°C to allow cells to attach. The media were removed and replaced with media containing hIL13 or its mutants (1 g/ml final concentration). The cells were incubated again overnight at 37°C. The next day, the media were removed, and the cells were fixed in ethanol and incubated with blocking medium (10% normal rabbit serum in PBS) at room temperature for 20 min. The blocking medium was removed, and goat anti-vascular cell adhesion molecule-1 (VCAM-1) antibody (1 g/ml) in 1.5% normal rabbit serum/ PBS was added. Cells were incubated at room temperature for 1 h and then primary antibody was removed and cells rinsed three times, 5 min each, with PBS. Cells were incubated with rabbit anti-goat IgG-Cy3 conjugate (1:150 dilution) in 1.5% normal rabbit serum/PBS for 45 min at room temperature, in the dark. After 45 min, the cells were rinsed three times, 5 min each, with PBS; a coverslip was mounted using aqueous mounting medium, and the fluorescent staining was determined using a rhodamine filter set. Images were obtained from the same experiment without adjusting the microscope between samples on a Zeiss Axioplan microscope and captured digitally using Snappy by Play Inc.
Cytotoxicity Blocking Assay-Glioblastoma cells (U-251 MG and SNB-19) were plated into 96-well culture plates and incubated for 24 h. After 24 h, hIL13 or its mutants were added to cells and incubated for 1 h at 37°C. An equal volume of 0.1% bovine serum albumin in PBS was added to cells for assays without blocking ligand. After the hour incubation, increasing concentration of the hIL13 chimeric toxin (hIL13-CTX) (21) was added (0.001-10 ng/ml final concentration), and the cells were incubated for 3 days. After 3 days, the number of proliferating cells in each well was determined using the colorimetric MTS/PMS method described above. The wells with cells treated with high concentrations of cycloheximide served as background for the assay.
RESULTS
Recombinant Protein Isolation and Purification-The prokaryotic production of the cytokines or their mutants under control of the T7 promoter was very efficient. After purification, between 0.5 and 1.5 mg of each cytokine or mutant was obtained from a 1-liter culture. When each purified protein was analyzed using SDS-PAGE and stained with Coomassie Blue, a single protein band was observed migrating at approximately 13 kDa (Fig. 1, panel A) . Visual inspection estimate suggested that all preparations are greater than 95% pure. The corresponding Western blot of the samples indicated that the isolated proteins were immunoreactive hIL13 or mutants thereof, since they reacted specifically with a goat polyclonal anti-hIL13 antibody, which lacks cross-reactivity with any other cytokine (Fig. 1, panel B) . The ␣-helix D mutants hIL13.R109D and hIL13.F113D were immunoreactive toward the same antibody as well (data not shown). Traces of a dimeric form (ϳ26 kDa) of some of the mutated cytokines were also detected.
All Studied Mutants Exhibit ␣-Helical Structure-To determine whether the recombinant interleukins had refolded correctly and that their mutation had not destroyed their general pattern of conformation, circular dichroism (CD) was used to determine the folded structure of the proteins. The secondary structure data from the spectropolarimeter indicated that each protein sample produced a spectrum consistent with an ␣-helical-enriched protein, having two spectral minima at approximately 208 and 222 nm (Fig. 2) . Furthermore, the CD spectrum of each mutant could be superimposed on the CD spectrum of the wild-type hIL13, although slight variations in spectra in- 
FIG. 1. SDS-PAGE (panel A) and Western blot (panel B)
analysis of purified human interleukin 13 and its mutants. Five hundred nanograms of each purified cytokine was loaded per sample. Proteins were detected using a Coomassie Blue stain, panel A. Separated proteins from a duplicate gel were electroblotted to a polyvinylidene difluoride membrane and detected with an anti-hIL13 antibody in a Western blot protocol using an enhanced chemiluminescence detection system, panel B.
tensity were observed between samples (Fig. 2, panels A-C) . hIL13.R109D and hIL13.F113D both produced CD spectra similar to the other mutants (not shown). For comparison, the CD spectrum of unfolded hIL13 was also obtained (Fig. 2, panel D) . The panel illustrates the collapse of the characteristic ␣-helical pattern when the protein is unfolded.
Various IL13 Mutants Induce TF-1 Cell Proliferation with Different Potencies-Since hIL13 does not bind the p140 subunit of the shared IL13/4 receptor complex by itself (17) , direct binding measurements between hIL13 and p140 subunit cannot be obtained. Therefore, we employed functional assays as a measure of the association of hIL13 with the shared IL13/4 receptor complex. To determine whether the IL13 mutants had an altered association with the shared signaling IL13/4 receptor, their induced TF-1 cell proliferative response was measured. TF-1 cells proliferate in a dose-dependent manner in the presence of hIL13 or hIL4 since they express the shared IL13/4 receptor (11, 18, 28) . Under our experimental conditions, at a concentration of 100 ng/ml, wild-type hIL13 consistently produces a maximal proliferative response in TF-1 cells of ϳ300% that of the base-line value (Fig. 3, panel A) . Differences were observed in TF-1 cell proliferation depending on whether the mutants were in the predicted ␣-helices A, C, or D.
The ␣-helix A mutants showed both an inability as well as a preserved ability to induce proliferation, approaching and even surpassing that caused by wild-type hIL13 (Fig. 3, panels A and  B) . In accordance with previous data, hIL13.E13K showed a minimal proliferative response over the range tested (Fig. 3,  panel B) . Similarly, other mutants at position 13 failed to induce a proliferative response compared with native hIL13. These included hIL13.E13I, hIL13.E13S, and hIL13.E13Y (Fig.  3, panel B) . Other mutants as this position showed contrasting activities to that of hIL13.E13K. Mutants hIL13.E13D and, unexpectedly, hIL13.E13R both induced a dose-dependent proliferation of TF-1 cells. Their induction of TF-1 cell proliferation followed the same pattern as wild-type hIL13, although hIL13.E13D had lesser effect on proliferation as hIL13.E13R (Fig. 3, panel A) . The other two ␣-helix A mutants were hIL13.E16K and hIL13.E17K, with mutated sites one turn of the ␣-helix up from position 13. Both induced a dose-dependent response in TF-1 cell stimulation (Fig. 3, panel A) . hIL13.E17K-induced effect was comparable to wild-type hIL13; however, hIL13.E16K exhibited a stimulation of TF-1 cell proliferation significantly greater than wild-type hIL13. The ␣-helix C mutants, hIL13.R66D and hIL13.S69D, both showed a significant impairment to stimulate TF-1 cells, compared with wild-type hIL13 (Fig. 3, panel C) , although their action on TF-1 cells can be classified between that caused by mutants shown in Fig. 3 , panels A and B. The ␣-helix D mutants also exhibited contrasting patterns of their action on TF-1 cells. Thus, hIL13.F113D was equivalent to wild-type hIL13 in inducing TF-1 cell proliferation contrary to the hIL13.R109D mutant, which was inactive on these cells (not shown).
IL13 Mutants Vary in Inducing the VCAM-1 Expression on HUVEC Cells-TF-1 cells have been characterized to possess
the shared IL13/4 receptor and induce a detectable biological response to signaling through the receptor (11, 18, 28) . However, TF-1 cells are pre-leukemic cells. Therefore, to test further the ability of the hIL13 mutants to interact with the shared hIL13/4 receptor on normal cells, the cytokine-induced expression of VCAM-1 on the surface of HUVEC was assayed. (Fig. 4, panels A and G) . In contrast, cells incubated overnight in media containing wild-type hIL13 had a marked increase in VCAM-1 (Fig. 4, panels B and  H) . The pattern of the staining appeared to be specific for certain areas of the cell surface, compared with the minimal, homogeneous staining of cells that had not been incubated with cytokine (Fig. 4, panels A and G) . Cells incubated with mutants hIL13.E13I, hIL13.E13K, and hIL13.E13Y, which are unable to induce TF-1 cell proliferation (Fig. 3) , had a diminished VCAM-1 expression compared with wild-type hIL13 (Fig. 4,  panels C, D, F, and B, respectively) . The residual activity of some solitary mutants may reflect the presence of another site in the interleukin, in ␣-helix C or D, that is involved in the signaling through the IL13/4 receptor, which is compatible with the TF-1 data. Although mutant hIL13.F113D was not 
FIG. 4.
Indirect immunofluorescence analysis of HUVEC VCAM-1 expression induced by human interleukin 13 or its mutants. Panels A-F and G-J are from two separate experiments, each with its own set of controls. HUVEC were cultured overnight in media containing buffer alone (panels A and G) or 1 g/ml either wild-type hIL13 (panels B and H) or its mutants (panels C-F, I and J). Induced expression of the protein was detected through a rhodamine filter using goat anti-VCAM-1 IgG primary antibody and rabbit anti-goat IgG CY3-conjugated secondary antibody. The sensitivity of the imaging camera was set to detect the level of fluorescence in the control field, panels A and G. No further adjustments were made to the sensitivity, allowing for the amount of increased or decreased fluorescence in the experimental fields to be directly related to the amount of interleukin-induced VCAM-1 expression. Photomicrographs are shown at lower magnification (ϫ 20) to increase the number of cells seen per field.
tested, the hIL13.R109D-induced VCAM-1 staining was negligible (not shown), suggesting again the involvement of ␣-helix D of the cytokine in effective signaling through the shared receptor. Mutants hIL13.E13R and hIL13.E17K showed VCAM-1 staining, similar to wild-type hIL13, when compared with their respective controls (Fig. 4, panels E and J) . Mutant hIL13.E16K appeared to have a superagonistic effect on VCAM-1 expression compared with its wild-type IL13 control (Fig. 4, panels I and H, respectively) . The enhanced specific VCAM-1 staining, induced by hIL13.E16K, supports its enhanced signaling through the shared receptor, as was seen in the TF-1 cell proliferation assays. The VCAM-1 staining data for hIL13.E13R and hIL13.E17K are also corroborated by the data obtained on TF-1 cells.
All ␣-Helix A and C but Not All ␣-Helix D Mutants of hIL13 Neutralize the Cytotoxicity of IL13-based Cytotoxins on Human Malignant Glioma Cells-We have shown that certain cancers are sensitive to chimeric cytotoxins composed of hIL13 and derivatives of a bacterial toxin, Pseudomonas exotoxin (19, 20) . These cytotoxins kill, e.g. human glioma cells very potently and specifically in an IL4-independent manner since only an excess of wild-type hIL13 and not hIL4 neutralizes their effect (20, 21) . To determine whether the hIL13 mutants competed for the same site(s) on glioblastoma cells as the hIL13 chimeric cytotoxin, a cytotoxicity neutralization assay was performed. The ability of hIL13 and its mutants to block the cancer-restrictive hIL13 receptor on two different human glioblastoma cell lines was determined. The cytotoxin used in the study, hIL13-CTX, is an extremely potent anti-tumor agent on glioma cells (20, 21) , including U-251 MG cells (Fig. 5, panel A) and SNB-19 cells (Fig. 5, panel B) , when the cells are cultured in the absence of a competing ligand for the receptor. Compared with tests without competitive ligand, cells survived even at the highest concentration of cytotoxin used when cultured in the presence of hIL13 or any of its A-or C-helix mutants (Fig. 5,  panels A and B) . IC 50 values for tests without blocking ligand were 0.1 ng/ml (1.25 pM) for U-251 MG cells and 0.07 ng/ml (0.875 pM) for SNB-19 cells. In contrast, the blocking assay using hIL13 mutants showed their ability to increase the IC 50 by at least 100 times. For concentrations of hIL13 or its mutants up to 1000 ϫ (by weight) over hIL13-CTX, no discernible differences were detected between these various mutants and wild-type hIL13 in blocking the activity of the cytotoxin on the glioma cells (Fig. 5, panels A and B) . Again, hIL13.F113D, an ␣-helix D mutant, behaved as the wild-type cytokine, contrary to hIL13.R109D, which was not able to compete for the killing activity of cytotoxin on glioma cells (not shown). As previously mentioned, hIL4 does not have any neutralizing activity in these assays (20, 21) . Therefore, the hIL13 mutants with diverse signaling actions through the shared hIL13/4 receptor all competed efficiently for the IL4-independent, cancer-associated receptor, with the exception of hIL13.R109D. DISCUSSION We report here areas of hIL13 needed for effective interaction with its respective receptors. The data suggest that the region of hIL13 that interacts with the cancer-associated receptor is mainly separate from but may be partially shared with the areas involved in activation of the shared IL13/4 receptor.
Our previous study revealed a single site mutant of hIL13 in ␣-helix A, hIL13.E13K, which showed minimal signaling through the shared IL13/4 receptor but retained the ability to interact with the glioma-associated receptor (24) . Other position 13 mutants examined here unexpectedly exhibited a nonuniform role of this site in the association of hIL13 with the shared IL13/4 receptor. For example, the substitution of wildtype glutamic acid with lysine in the hIL13.E13K mutant suggested a possible charge requirement for efficient ligand-receptor interaction. Supporting this, when wild-type glutamic acid was substituted with aspartic acid, a signaling phenotype was obtained, albeit with less activity when compared with wildtype hIL13. However, another mutant, which incorporates the positively charged amino acid arginine at position 13, demonstrated a signaling phenotype. In fact, hIL13.E13R was as potent as wild-type hIL13. Phenotypically, the hIL13.E13R mutant is opposite of hIL13.E13K. This result suggests that electrostatics are not the only force determining the efficient interaction of hIL13 with the shared receptor complex. Others have observed that a substitution of arginine for lysine in the active site of some enzymes can completely abolish activity (29) . Structurally, single lysine to arginine mutations have been reported to severely affect and angles of peptide bonds, leading to a strained conformation and reduced protein function (30) . Other position 13 mutations that caused loss of interaction with the shared IL13/4 receptor encompass amino acids with small polar side chains (serine), bulky polar side chains (tyrosine), and large non-polar side chains (isoleucine), again suggesting that the observed effect is due to a combination of factors, such as amino acid size and polarity.
In contrast to our expectation, both "glutamic acid to lysine" mutations in positions 16 and 17 of hIL13 did not disrupt the ability of hIL13 to associate with the hIL13/4 receptor. In fact, the mutation at position 16 appeared to enhance the interaction of the cytokine with the hIL13/4 receptor, since its action on TF-1 cells was even greater than wild-type hIL13 and it caused an enhanced specific VCAM-1 expression on HUVEC cells. Modeling information from helix A indicates the point mutations that disrupt interaction with the shared receptor, and the point mutations that maintain and even enhance its interaction with the shared receptor are separated only by 5 Å (8). These data suggest the site(s) in the putative A-helix of hIL13 that interacts with the shared hIL13/4 receptor is indeed in the vicinity of position 13 in hIL13.
The C-helix of hIL13 is also involved in the interaction with the shared hIL13/4 receptor, since both mutants hIL13.R66D and hIL13.S69D resulted in reduced signaling through the receptor. The fact that all A-and C-helix mutations alter the interaction with the shared receptor suggests that a surface of hIL13, comprised mainly of these areas, most likely contacts the p140 subunit of the shared receptor once bound to the lower molecular mass (52 kDa) IL13 subunit (14 -16) .
With exception of position 109, the regions of hIL13 that interact with the shared receptor are separate from the region(s) involved in the interaction with the glioma-associated receptor. This is because all A-and C-helix mutants competed for the IL4-independent, internalized receptor on malignant glioma cells. Areas of hIL13 that may be responsible for interaction with the glioma-associated receptor include helices B and D, a small region of ␤-sheet structure, or the stretches of protein between them (8) .
Mutational analysis in ␣-helix D identified hIL13.R109D that not only failed to signal through the IL13/4 shared receptor but was the first and only mutant studied that lost its ability to interact with the glioma-associated receptor, despite evidence for its proper folding. The results suggest that position 109 of hIL13 may be directly contributing to the area needed for efficient association with the IL4-independent IL13 receptor found on certain cancer cells. This is also the only mutant in which the area needed for interaction with both IL13 receptors is shared. In contrast to the 109 mutant, another ␣-helix D mutant, hIL13.Y113D, unlike its IL4 antagonistic homolog, transduced signal through the shared receptor simi-larly to hIL13. In addition, it was able to block the action of hIL13-based cytotoxins on glioma cells, suggesting that this site may not contribute to the site recognized by the gliomaassociated receptor. Like the small distance between ␣-helix A mutants that resulted in loss and gain of function, position 109 that contributes to the binding of hIL13 to the glioma-associated receptor and position 113 that does not are separated only by a single helical turn. These data also emphasize that although the alignment approach proved successful in identifying the importance of ␣-helices A and C of hIL13 in specific functional signaling through the shared receptor, apparent differences between hIL13 and hIL4 systems exist.
In summary, this is the first report using several site-specific mutants to identify the areas of hIL13 needed for its effective interaction with its two known receptors. Helices A, C, and D in hIL13 contribute to its interaction with the shared IL13/4 receptor. Our findings may have important bearing on a possible utility of hIL13, or vectors based on hIL13, in the management of brain tumors (20, 24) or asthma (31, 32) . In our unique approach we are able to change a natural endogenous compound for the purpose of redirecting it toward either its malignancy-related receptor or its immunophysiologically related receptor. Our approach differs from the conventional strategies by eliminating the need for separate cell type-specific antibodies or adding other agents to obtain the desired, specific recognition of cells.
